Abstract
Osteoclasts are unique multinucleated cells that can resorb bone. Bone mass is determined by a tightly regulated balance between osteoclasts and osteoblasts, which generate bones. Thus, the excessive formation of osteoclasts leads to the pathological bone resorption observed in postmenopausal osteoporosis, rheumatoid arthritis, Paget’s disease, and bone tumor metastases. During osteoclast differentiation, NF-κB is activated by TRAF6-mediated signals from RANK expressed on the surface of osteoclast progenitor cells upon RANKL stimulation, activating NFATc1, a master transcription factor in osteoclastogenesis. However, in contrast regular NF-κB activation, sufficient NFATc1 activation requires long-term activation of NF-κB, which can be induced uniquely by RANK but not by CD40, a receptor that also uses TRAF6 to activate NF-κB. Through analysis of various RANK mutants, we identified the 60-amino-acid HCR domain (mouse RANK) in the cytoplasmic tail of RANK. HCR is highly conserved among vertebrates and is crucial for long-term NF-κB activation. Interestingly, when HCR was attached to the cytoplasmic tail of CD40, the chimeric receptor promoted osteoclast formation, even though CD40 itself cannot. In this chapter, we explore the molecular mechanisms of HCR-mediated signals and the possible application of the HCR peptide as an anti-bone-resorptive drug.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Akiyama T, Shimo Y, Yanai H, Qin J, Ohshima D, Maruyama Y, Asaumi Y, Kitazawa J, Takayanagi H, Penninger JM, Matsumoto M, Nitta T, Takahama Y, Inoue J (2008) The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29(3):423–437. doi:10.1016/j.immuni.2008.06.015
Asagiri M, Sato K, Usami T, Ochi S, Nishina H, Yoshida H, Morita I, Wagner EF, Mak TW, Serfling E, Takayanagi H (2005) Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202(9):1261–1269. doi:10.1084/jem.20051150
Blair HC, Teitelbaum SL, Ghiselli R, Gluck S (1989) Osteoclastic bone resorption by a polarized vacuolar proton pump. Science 245(4920):855–857
Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin AC, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, Superti-Furga G (2004) A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 6(2):97–105. doi:10.1038/ncb1086
Brooks H, Lebleu B, Vives E (2005) Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev 57(4):559–577. doi:10.1016/j.addr.2004.12.001
Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, van der Heijde D, Zhou L, Tsuji W, Newmark R (2008) Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 58(5):1299–1309. doi:10.1002/art.23417
Colonna M (2003) TREMs in the immune system and beyond. Nat Rev Immunol 3(6):445–453. doi:10.1038/nri1106
Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. doi:10.1056/NEJMoa0809493
Darnay BG, Ni J, Moore PA, Aggarwal BB (1999) Activation of NF-κB by RANK requires tumor necrosis factor receptor-associated factor (TRAF) 6 and NF-κB-inducing kinase. Identification of a novel TRAF6 interaction motif. J Biol Chem 274(12):7724–7731
Dietrich J, Cella M, Seiffert M, Buhring HJ, Colonna M (2000) Cutting edge: signal-regulatory protein β1 is a DAP12-associated activating receptor expressed in myeloid cells. J Immunol 164 (1):9–12. doi:10.4049/jimmunol.164.1.9
Dougall WC, Glaccum M, Charrier K, Rohrbach K, Brasel K, De Smedt T, Daro E, Smith J, Tometsko ME, Maliszewski CR, Armstrong A, Shen V, Bain S, Cosman D, Anderson D, Morrissey PJ, Peschon JJ, Schuh J (1999) RANK is essential for osteoclast and lymph node development. Genes Dev 13(18):2412–2424
Fata JE, Kong YY, Li J, Sasaki T, Irie-Sasaki J, Moorehead RA, Elliott R, Scully S, Voura EB, Lacey DL, Boyle WJ, Khokha R, Penninger JM (2000) The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. Cell 103(1):41–50. doi:10.1016/S0092-8674(00)00103-3
Fizazi K, Lipton A, Mariette X, Body JJ, Rahim Y, Gralow JR, Gao G, Wu L, Sohn W, Jun S (2009) Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol 27(10):1564–1571. doi:10.1200/JCO.2008.19.2146
Franzoso G, Carlson L, Xing L, Poljak L, Shores EW, Brown KD, Leonardi A, Tran T, Boyce BF, Siebenlist U (1997) Requirement for NF-κB in osteoclast and B-cell development. Genes Dev 11(24):3482–3496
Futaki S, Suzuki T, Ohashi W, Yagami T, Tanaka S, Ueda K, Sugiura Y (2001) Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J Biol Chem 276(8):5836–5840. doi:10.1074/jbc.M007540200
Galibert L, Tometsko ME, Anderson DM, Cosman D, Dougall WC (1998) The involvement of multiple tumor necrosis factor receptor (TNFR)-associated factors in the signaling mechanisms of receptor activator of NF-κB, a member of the TNFR superfamily. J Biol Chem 273(51):34120–34127
Gohda J, Akiyama T, Koga T, Takayanagi H, Tanaka S, Inoue J (2005) RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 24(4):790–799. doi:10.1038/sj.emboj.7600564
Hacker H, Karin M (2006) Regulation and function of IKK and IKK-related kinases. Sci STKE 2006(357):re13. doi:10.1126/stke.3572006re13
Hageman K, Patel KC, Mace K, Cooper MR (2013) The role of denosumab for prevention of skeletal-related complications in multiple myeloma. Ann Pharmacother 47(7–8):1069–1074. doi:10.1345/aph.1R776
Hanada R, Leibbrandt A, Hanada T, Kitaoka S, Furuyashiki T, Fujihara H, Trichereau J, Paolino M, Qadri F, Plehm R, Klaere S, Komnenovic V, Mimata H, Yoshimatsu H, Takahashi N, von Haeseler A, Bader M, Kilic SS, Ueta Y, Pifl C, Narumiya S, Penninger JM (2009) Central control of fever and female body temperature by RANKL/RANK. Nature (Lond) 462(7272):505–509. doi:10.1038/nature08596
Hayden MS, Ghosh S (2008) Shared principles in NF-κB signaling. Cell 132(3):344–362. doi:10.1016/j.cell.2008.01.020
Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ (1999) Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96(7):3540–3545
Inoue J, Ishida T, Tsukamoto N, Kobayashi N, Naito A, Azuma S, Yamamoto T (2000) Tumor necrosis factor receptor-associated factor (TRAF) family: adapter proteins that mediate cytokine signaling. Exp Cell Res 254(1):14–24. doi:10.1016/j.cell.2008.01.020
Iotsova V, Caamano J, Loy J, Yang Y, Lewin A, Bravo R (1997) Osteopetrosis in mice lacking NF-κB1 and NF-κB2. Nat Med 3(11):1285–1289
Ishida T, Mizushima S, Azuma S, Kobayashi N, Tojo T, Suzuki K, Aizawa S, Watanabe T, Mosialos G, Kieff E, Yamamoto T, Inoue J (1996) Identification of TRAF6, a novel tumor necrosis factor receptor-associated factor protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J Biol Chem 271(46):28745–28748
Josien R, Li HL, Ingulli E, Sarma S, Wong BR, Vologodskaia M, Steinman RM, Choi Y (2000) TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo. J Exp Med 191(3):495–502
Kaifu T, Nakahara J, Inui M, Mishima K, Momiyama T, Kaji M, Sugahara A, Koito H, Ujike-Asai A, Nakamura A, Kanazawa K, Tan-Takeuchi K, Iwasaki K, Yokoyama WM, Kudo A, Fujiwara M, Asou H, Takai T (2003) Osteopetrosis and thalamic hypomyelinosis with synaptic degeneration in DAP12-deficient mice. J Clin Invest 111(3):323–332. doi:10.1172/JCI16923
Kim N, Takami M, Rho J, Josien R, Choi Y (2002) A novel member of the leukocyte receptor complex regulates osteoclast differentiation. J Exp Med 195(2):201–209
Kim N, Kadono Y, Takami M, Lee J, Lee SH, Okada F, Kim JH, Kobayashi T, Odgren PR, Nakano H, Yeh WC, Lee SK, Lorenzo JA, Choi Y (2005) Osteoclast differentiation independent of the TRANCE-RANK-TRAF6 axis. J Exp Med 202(5):589–595. doi:10.1084/jem.20050978
Kim H, Choi HK, Shin JH, Kim KH, Huh JY, Lee SA, Ko CY, Kim HS, Shin HI, Lee HJ, Jeong D, Kim N, Choi Y, Lee SY (2009) Selective inhibition of RANK blocks osteoclast maturation and function and prevents bone loss in mice. J Clin Invest 119(4):813–825. doi:10.1172/JCI36809
Kobayashi N, Kadono Y, Naito A, Matsumoto K, Yamamoto T, Tanaka S, Inoue J (2001) Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis. EMBO J 20(6):1271–1280. doi:10.1093/emboj/20.6.1271
Koga T, Inui M, Inoue K, Kim S, Suematsu A, Kobayashi E, Iwata T, Ohnishi H, Matozaki T, Kodama T, Taniguchi T, Takayanagi H, Takai T (2004) Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature (Lond) 428(6984):758–763. doi:10.1038/nature02444
Kong YY, Yoshida H, Sarosi I, Tan HL, Timms E, Capparelli C, Morony S, Oliveira-dos-Santos AJ, Van G, Itie A, Khoo W, Wakeham A, Dunstan CR, Lacey DL, Mak TW, Boyle WJ, Penninger JM (1999) OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis. Nature (Lond) 397(6717):315–323. doi:10.1038/16852
Kosuge M, Takeuchi T, Nakase I, Jones AT, Futaki S (2008) Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. Bioconjug Chem 19(3):656–664. doi:10.1021/bc700289w
Kubagawa H, Burrows PD, Cooper MD (1997) A novel pair of immunoglobulin-like receptors expressed by B cells and myeloid cells. Proc Natl Acad Sci U S A 94(10):5261–5266
Liu S, Chen ZJ (2011) Expanding role of ubiquitination in NF-κB signaling. Cell Res 21(1):6–21. doi:10.1038/cr.2010.170
Lomaga MA, Yeh WC, Sarosi I, Duncan GS, Furlonger C, Ho A, Morony S, Capparelli C, Van G, Kaufman S, van der Heiden A, Itie A, Wakeham A, Khoo W, Sasaki T, Cao Z, Penninger JM, Paige CJ, Lacey DL, Dunstan CR, Boyle WJ, Goeddel DV, Mak TW (1999) TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. Genes Dev 13(8):1015–1024
Mao D, Epple H, Uthgenannt B, Novack DV, Faccio R (2006) PLCγ2 regulates osteoclastogenesis via its interaction with ITAM proteins and GAB2. J Clin Invest 116(11):2869–2879. doi:10.1172/JCI28775
Matsumoto M, Sudo T, Saito T, Osada H, Tsujimoto M (2000) Involvement of p38 mitogen-activated protein kinase signaling pathway in osteoclastogenesis mediated by receptor activator of NF-κB ligand (RANKL). J Biol Chem 275(40):31155–31161. doi:10.1074/jbc.M001229200
Naito A, Azuma S, Tanaka S, Miyazaki T, Takaki S, Takatsu K, Nakao K, Nakamura K, Katsuki M, Yamamoto T, Inoue J (1999) Severe osteopetrosis, defective interleukin-1 signalling and lymph node organogenesis in TRAF6-deficient mice. Genes Cells 4(6):353–362. doi:10.1046/j.1365-2443.1999.00265.x
Rodan GA, Martin TJ (2000) Therapeutic approaches to bone diseases. Science 289(5484):1508–1514. doi:10.1126/science.289.5484.1508
Schwarz P, Rasmussen AQ, Kvist TM, Andersen UB, Jorgensen NR (2012) Paget’s disease of the bone after treatment with Denosumab: a case report. Bone (NY) 50(5):1023–1025
Sun SC (2010) Controlling the fate of NIK: a central stage in noncanonical NF-κB signaling. Sci Signal 3(123):pe18. doi:10.1126/scisignal.3123pe18
Taguchi Y, Gohda J, Koga T, Takayanagi H, Inoue J (2009) A unique domain in RANK is required for Gab2 and PLCγ2 binding to establish osteoclastogenic signals. Genes Cells 14(11):1331–1345. doi:10.1111/j.1365-2443.2009.01351.x
Taguchi Y, Kiga Y, Gohda J, Inoue J (2012) Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of receptor activator of nuclear factor κB. J Bone Miner Metab 30(5):543–553. doi:10.1007/s00774-012-0353-5
Takai T, Li M, Sylvestre D, Clynes R, Ravetch JV (1994) FcRγ chain deletion results in pleiotrophic effector cell defects. Cell 76(3):519–529. doi:10.1016/0092-8674(94)90115-5
Takayanagi H (2007) Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7(4):292–304. doi:10.1038/nri2062
Takayanagi H, Iizuka H, Juji T, Nakagawa T, Yamamoto A, Miyazaki T, Koshihara Y, Oda H, Nakamura K, Tanaka S (2000) Involvement of receptor activator of nuclear factor κB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. Arthritis Rheum 43(2):259–269. doi:10.1002/1529-0131(200002)43:2<259::AID-ANR4>3.0.CO;2-W
Takayanagi H, Kim S, Koga T, Nishina H, Isshiki M, Yoshida H, Saiura A, Isobe M, Yokochi T, Inoue J, Wagner EF, Mak TW, Kodama T, Taniguchi T (2002) Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts. Dev Cell 3(6):889–901. doi:10.1016/S1534-5807(02)00369-6
Teitelbaum SL, Abu-Amer Y, Ross FP (1995) Molecular mechanisms of bone resorption. J Cell Biochem 59(1):1–10. doi:10.1002/jcb.240590102
Tomasello E, Cant C, Buhring HJ, Vely F, Andre P, Seiffert M, Ullrich A, Vivier E (2000) Association of signal-regulatory proteins β with KARAP/DAP-12. Eur J Immunol 30(8):2147–2156. doi:10.1002/1521-4141(2000)30:8<2147::AID-IMMU2147>3.0.CO;2-1
Vaananen HK, Karhukorpi EK, Sundquist K, Wallmark B, Roininen I, Hentunen T, Tuukkanen J, Lakkakorpi P (1990) Evidence for the presence of a proton pump of the vacuolar H(+)-ATPase type in the ruffled borders of osteoclasts. J Cell Biol 111(3):1305–1311
Wong BR, Josien R, Lee SY, Vologodskaia M, Steinman RM, Choi Y (1998) The TRAF family of signal transducers mediates NF-κB activation by the TRANCE receptor. J Biol Chem 273(43):28355–28359
Yamamoto A, Miyazaki T, Kadono Y, Takayanagi H, Miura T, Nishina H, Katada T, Wakabayashi K, Oda H, Nakamura K, Tanaka S (2002) Possible involvement of IκB kinase 2 and MKK7 in osteoclastogenesis induced by receptor activator of nuclear factor κB ligand. J Bone Miner Res 17(4):612–621. doi:10.1359/jbmr.2002.17.4.612
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Japan
About this chapter
Cite this chapter
Taguchi, Y., Gohda, J., Inoue, Ji. (2015). NF-κB Signaling in Osteoclastogenesis. In: Inoue, Ji., Takekawa, M. (eds) Protein Modifications in Pathogenic Dysregulation of Signaling. Springer, Tokyo. https://doi.org/10.1007/978-4-431-55561-2_13
Download citation
DOI: https://doi.org/10.1007/978-4-431-55561-2_13
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-55560-5
Online ISBN: 978-4-431-55561-2
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)